|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Samarth_Kulkarni
|
|
gptkbp:collaboratesWith
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:countryOfOrigin
|
gptkb:Switzerland
|
|
gptkbp:developedBy
|
gptkb:CTX001
gene-based medicines
|
|
gptkbp:focusesOn
|
gene editing
sickle cell disease
beta thalassemia
CRISPR/Cas9 technology
|
|
gptkbp:foundedBy
|
gptkb:Emmanuelle_Charpentier
gptkb:Daniel_Anderson
gptkb:Shaun_Foy
gptkb:Rodger_Novak
|
|
gptkbp:foundedIn
|
2013
|
|
gptkbp:headquartersLocation
|
gptkb:Boston,_Massachusetts,_United_States
gptkb:Zug,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CRISPR Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:notableProduct
|
exagamglogene autotemcel (exa-cel)
|
|
gptkbp:numberOfEmployees
|
over 300
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:technology
|
gptkb:CRISPR/Cas9
|
|
gptkbp:tradedOn
|
NASDAQ:CRSP
|
|
gptkbp:website
|
https://www.crisprtx.com/
|
|
gptkbp:bfsParent
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|